Zirconium silicate

Drug Profile

Zirconium silicate

Alternative Names: Lokelma; Sodium zirconium cyclosilicate; UXSi-9; Ziconite; Zircon; ZS; ZS 9

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZS Pharma
  • Class Heavy metals; Minerals; Silicates; Transition elements
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hyperkalaemia

Most Recent Events

  • 17 Nov 2017 AstraZeneca plans the phase II ENERGIZE trial for Hyperkalaemia (Adjunctive therapy) in January 2018 (NCT03337477)
  • 09 Oct 2017 AstraZeneca plans a phase III trial for Hyperkalaemia in USA and Russia (NCT03303521)
  • 18 Sep 2017 AstraZeneca plans a phase I trial for Hyperkalaemia (In volunteers) in Hong Kong (PO) in October 2017 (NCT03283267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top